论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
miR-934 作为一种预后标志物,可通过靶向 PROX1 促进胰腺肿瘤细胞的增殖和迁移
Authors Jin Y, Weng Y, Wang Y, Lin J, Deng X, Shen B, Zhan Q, Lu X
Received 13 February 2020
Accepted for publication 6 April 2020
Published 22 April 2020 Volume 2020:13 Pages 3389—3399
DOI https://doi.org/10.2147/OTT.S249662
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr XuYu Yang
Background: Pancreatic cancer is an extremely lethal digestive cancer with late diagnosis and poor prognosis. miR-934 has been reported to serve as an oncogene in multiple cancers, such as ovarian cancer and bladder cancer. However, its role in pancreatic cancer remains undiscovered.
Materials and Methods: The expression data of miR-934 were obtained from the Gene Expression Omnibus database and from our own patient samples. The clinicopathological data and corresponding follow-up data were retrieved from The Cancer Genome Atlas database. CCK8 and colony formation assays were conducted to measure cell proliferation capacity in vitro. Wound healing and transwell assays were performed to detect the migration ability of pancreatic cancer cell.
Results: We found that miR-934 was significantly upregulated in pancreatic tumor samples and cell lines. The expression of miR-934 was related to pathological stages. Upregulated miR-934 was associated with poor prognosis in patients with pancreatic cancer. Mir-934 inhibition reduced, while overexpression promoted, cell proliferation and migration. Mechanically, we found miR-934 could directly bind to 3ʹ-UTR of PROX1 leading to mRNA derogation. Furthermore, increased cell proliferation and migration caused by miR-934 overexpression could be reversed by forced PROX1 expression.
Conclusion: miR-934 is an oncogene in pancreatic cancer and could serve as a prognosis indicator for patients with pancreatic cancer, suggesting that miR-934 is a promising therapeutic target for pancreatic cancer.
Keywords: miR-934, PROX1, proliferation, metastasis, pancreatic cancer